

References

L-171

1. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*. 2011 Jun 30;364(26):2507-16. Available at: www.nejm.org/doi/pdf/10.1056/NEJMoa1103782
2. Vemurafenib (ZELBORAF™) prescribing information. August 2011. 3. Long G, Menzie AM, Nagrial AM, et al. Prognostic and clinicopathic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*. 2011;29:1239-46. Available at: www.gene.com/gene/products/information/zelboraf/pdf/pi.pdf
3. Long G, Menzie AM, Nagrial AM, et al. Prognostic and clinicopathic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*. 2011;29:1239-46.
4. National Comprehensive Cancer Network: Practice Guidelines in Oncology. Melanoma (v.3.2016.) Available at: www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
5. Dabrafenib (Tafinlar®) prescribing information. Jan 2014. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf
6. Trametinib (Mekinist®) prescribing information. Jan 2014. Available at www.pharma.us.novartis.com/product/pi/pdf/mekinist.pdf
7. Cobimetinib (Cotellic®) prescribing information 2015. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf